Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 8;20(2):274–283. doi: 10.1158/1535-7163.MCT-20-0567

Figure 5. Molecular characterization of WRJ388 cells.

Figure 5.

(A) Immunoblot analysis of WRJ388, T2 (KrasG12DLkb1−/−p53−/−), and 634 (KrasG12Dp53−/−) cell lysate with indicated antibodies. (B) SRB analysis of leflunomide dose-response in WRJ388 cells at Days 1–4. (C) Uridine rescue of WRJ388 cells treated with 50 μM leflunomide at 72 hrs. (D) Cell cycle analysis of WRJ388 cells treated with 50 μM leflunomide, 2.5 mM uridine, or their combinations at 72 hrs. (E) Annexin-V/7AAD flow cytometry analysis of WRJ388 cells treated with 0, 50, or 200 μM of leflunomide for 72 hrs.